Your browser doesn't support javascript.
loading
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff, Julie N; Beer, Tomasz M; Alumkal, Joshi J; Slottke, Rachel E; Redmond, William L; Thomas, George V; Thompson, Reid F; Wood, Mary A; Koguchi, Yoshinobu; Chen, Yiyi; Latour, Emile; Bergan, Raymond C; Drake, Charles G; Moran, Amy E.
Afiliación
  • Graff JN; Division of Hospitalist and Specialty Medicine, Portland VA Medical Center, Portland, Oregon, USA graffj@ohsu.edu.
  • Beer TM; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Alumkal JJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Slottke RE; Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
  • Redmond WL; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Thomas GV; Earle A. Chiles Research Institute, Portland, Oregon, USA.
  • Thompson RF; Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Wood MA; Division of Hospitalist and Specialty Medicine, Portland VA Medical Center, Portland, Oregon, USA.
  • Koguchi Y; Department of Radiation Medicine, Department of Biomedical Engineering, Computational Biology Program, Oregon Health & Science University, Portland, Oregon, USA.
  • Chen Y; Division of Hospitalist and Specialty Medicine, Portland VA Medical Center, Portland, Oregon, USA.
  • Latour E; Earle A. Chiles Research Institute, Portland, Oregon, USA.
  • Bergan RC; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Drake CG; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Moran AE; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
J Immunother Cancer ; 8(2)2020 07.
Article en En | MEDLINE | ID: mdl-32616555
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feniltiohidantoína / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Neoplasias de la Próstata Resistentes a la Castración / Nitrilos Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feniltiohidantoína / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Neoplasias de la Próstata Resistentes a la Castración / Nitrilos Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido